KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Non-Current Assets: 2015-2025

Historic Non-Current Assets for CRISPR Therapeutics AG (CRSP) over the last 9 years, with Sep 2025 value amounting to $316.2 million.

  • CRISPR Therapeutics AG's Non-Current Assets rose 1.27% to $316.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $316.2 million, marking a year-over-year increase of 1.27%. This contributed to the annual value of $304.9 million for FY2024, which is 5.16% down from last year.
  • Latest data reveals that CRISPR Therapeutics AG reported Non-Current Assets of $316.2 million as of Q3 2025, which was up 6.81% from $296.0 million recorded in Q2 2025.
  • In the past 5 years, CRISPR Therapeutics AG's Non-Current Assets ranged from a high of $420.7 million in Q3 2022 and a low of $125.6 million during Q1 2021.
  • Over the past 3 years, CRISPR Therapeutics AG's median Non-Current Assets value was $319.4 million (recorded in 2024), while the average stood at $318.0 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first surged by 244.29% in 2021, then dropped by 22.44% in 2023.
  • CRISPR Therapeutics AG's Non-Current Assets (Quarterly) stood at $334.4 million in 2021, then grew by 16.65% to $390.0 million in 2022, then declined by 17.57% to $321.5 million in 2023, then declined by 5.16% to $304.9 million in 2024, then climbed by 1.27% to $316.2 million in 2025.
  • Its last three reported values are $316.2 million in Q3 2025, $296.0 million for Q2 2025, and $298.5 million during Q1 2025.